THERACLION news, videos and press releases
For more news please use our advanced search feature.
THERACLION - More news...
THERACLION - More news...
- Theraclion Executes Strategy in First Half
- Theraclion Announces the Success of Its Capital Increase
- Theraclion Announces Strategic Partnership, Capital Raise and CEO Appointment
- THERACLION Announces 2022 Financial Results and Informs on the Company’s Short-Term Financing
- FDA Approval for Pivotal Varicose Veins Study With Theraclion’s SONOVEIN®
- Theraclion Announces Results of First US Trial
- Theraclion Reaches Major Milestones in 2022, Paving the Way for the Commercial Deployment of SONOVEIN®
- University of Virginia (UVA) Cancer Center to Use Theraclion's HD Technology
- Theraclion Sucessfully Representated at the 8th International Symposium on Focused Ultrasound
- THERACLION: Last Patient of First SONOVEIN® US Study Has Been Treated
- Theraclion: New Echotherapy for Varicose Veins Partnership With Parisian Region Hospital Wound Center Announced
- Theraclion: The New Strategy Is Paying Off
- Theraclion: a Harvest of Good News
- Theraclion: 95% Vein Occlusion Rate: Results Presented by Dr Stalnikiewicz at the Swiss Vein Days 2022
- THERACLION: HIFU and their Use in Immune-oncology Presented at the Annual Scientific Meeting of the Society of Interventional Radiology in Boston
- Theraclion Launches Its New Robotic Vein Platform SONOVEIN® HD
- First Patients Treated With Theraclion's SONOVEIN® in the US
- Theraclion Announces 1,000th Treatment for Varicose Veins with SONOVEIN ®
- 2021 Results in Line with Theraclion's Development Strategy for 2022
- Theraclion Announces First Patient Inclusion in Early-Stage Breast Cancer Study
- Theraclion Ready to Scale up in 2022
- Yann Duchesne Appointed New Executive Chairman to Lead Major Shift in Theraclion’s Strategy
- Theraclion’s First Varicose Veins Treatment in Hong-Kong Opens Perspectives in Asia
- Theraclion Results Show Strong Recovery, Allowing Ambitious Plans
- FDA Approves the 1st Trial with Theraclion's Vein Therapy in the US
- Theraclion's Sales Multiplied by 5 in The First Half of 2021
- CORRECTING and REPLACING: Theraclion Strengthens Its Board of Directors
- Theraclion Strengthens its Board of Directors
- Evolution in Theraclion's Capital: Bernard Sabrier and Unigestion Pass the 20% Threshold, Proof of Confidence in the Company's Development
- UVA Cancer Center to Expand Use of Theraclion’s HIFU System in Cancer Treatment Research
